Considering these complex interactions, we would like to emphasize the urgent need to develop new, orthotopic, immunocompetent models of GBM that would allow detailed study of the multifaceted effects of PARP inhibition and their consequences on cell survival, neuroinflammation, and cognition in the context of a tumor bearing brain with an intact immune system. This evidence concerns the gene PARP1 and glioblastoma.